References

10.1016/s0140-6736(26)01092-5

10.1016/s0140-6736(26)01092-5 · External reference

Unresolved reference

External reference

Radiographic progression-free survival and clinical progression-free survival as potential surrogates for overall survival in men with metastatic hormone-sensitive prostate cancer

10.1200/jco.23.01535 · 2024 · External reference

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

10.1016/s1470-2045(24)00440-6 · 2024 · External reference

177Lu-PSMA-617 consolidation therapy after docetaxel in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer: a randomized, phase 2 trial

2025 · External reference

177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase II study

10.1200/jco-25-01553 · 2025 · External reference

Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4

10.1200/jco-25-02834 · 2026 · External reference

Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade

10.2967/jnumed.118.223099 · 2019 · External reference

Unresolved reference

External reference

Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer

10.1038/s43018-023-00539-6 · 2023 · External reference

Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity

10.1158/1078-0432.ccr-19-1485 · 2020 · External reference